ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.

ETFOptimize | HOME
Close Window

Drug Discovery: Spotlight on Creative Biolabs’ Enhanced Next-Generation Probiotics Library

By: Get News
In early April, Creative Biolabs integrated its technical resources to advance live biotherapeutic drug discovery, culminating in the recent update of its next-generation probiotics library.

New York, USA - May 21, 2024 - Traditional probiotics are widely recognized for promoting gut health and immune function. Next-generation probiotics (NGPs) further broaden their application prospects. "NGPs show significant potential in preventing and treating various chronic diseases," according to a scientist at Creative Biolabs, "and our updated library gathers diverse microbial strains with unique probiotic potential, providing robust support for drug discovery and development."

Many potential NGPs have been identified or are currently under intensive development. The updated NGP library spans from aerobic to anaerobic bacteria, covering a wide range of microbial strains with distinct probiotic effects, customized to meet specific research needs.

Diversified Probiotic Library

Creative Biolabs has introduced the development of Oxalobacter formigenes, which reduces the risk of kidney stone formation by degrading oxalate in the body. "This updated library includes gram-negative, oxalate-degrading anaerobic bacteria isolated from human feces and sheep rumen," the scientist explained. "If there are specific experimental needs, our team can also customize strains."

For researchers focused on gut health, enhancing gut barrier function, and anti-inflammatory effects, Creative Biolabs' next-generation probiotics library offers Butyricicoccus pullicaecorum and Eubacterium hallii. "Though these two strains operate via different mechanisms, they are both star candidates for diseases related to dysbiosis."

Additionally, Creative Biolabs provides development services for Parabacteroides goldsteinii to experts studying obesity. This bacterium plays a crucial role in carbohydrate metabolism and the production of short-chain fatty acids. "Our research has confirmed anti-obesity potential in high-fat diet-induced obese mice."

Cutting-Edge Technological Platform

The next-generation probiotics library at Creative Biolabs leverages the latest next-generation sequencing and bioinformatics platforms, enabling in-depth analysis of microbial communities. These advanced technologies not only facilitate the identification and characterization of new microorganisms with probiotic effects but also analyze their genomic structure and functional genes.

"NGS technology allows for rapid, efficient analysis of complex microbial communities, showcasing microbial diversity and abundance. Our laboratory team can obtain more rare and unique microbial resources at the first step of microbial isolation and screening."

In addition to microbial isolation and screening, the next-generation probiotics platform offers the following strain development services, including but not limited to:

* Microbial identification

* Antibiotic sensitivity/resistance testing

* Carbohydrate fermentation profiling

* Microbial purification

For more information about the NGP library, please visit


Creative Biolabs is a global biotechnology company specializing in live biotherapeutic product development. By continually updating and expanding its NGP library, Creative Biolabs' experts collaborate closely with leading research institutions worldwide to explore the potential of microorganisms in health and disease.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


IntelligentValue Home
Close Window


All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017, a publication of Optimized Investments, Inc. All rights reserved.